CN103154242B - 诺如病毒衍生的免疫原性组合物和方法 - Google Patents

诺如病毒衍生的免疫原性组合物和方法 Download PDF

Info

Publication number
CN103154242B
CN103154242B CN201180042647.5A CN201180042647A CN103154242B CN 103154242 B CN103154242 B CN 103154242B CN 201180042647 A CN201180042647 A CN 201180042647A CN 103154242 B CN103154242 B CN 103154242B
Authority
CN
China
Prior art keywords
norovirus
strain
chimeric
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180042647.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103154242A (zh
Inventor
E·塞滕布里
A·梅迪纳-塞尔比
D·科伊特
P·道米策
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103154242A publication Critical patent/CN103154242A/zh
Application granted granted Critical
Publication of CN103154242B publication Critical patent/CN103154242B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180042647.5A 2010-07-06 2011-07-05 诺如病毒衍生的免疫原性组合物和方法 Active CN103154242B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36158110P 2010-07-06 2010-07-06
US61/361,581 2010-07-06
PCT/US2011/042979 WO2012006293A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods

Publications (2)

Publication Number Publication Date
CN103154242A CN103154242A (zh) 2013-06-12
CN103154242B true CN103154242B (zh) 2015-09-30

Family

ID=44628871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180042647.5A Active CN103154242B (zh) 2010-07-06 2011-07-05 诺如病毒衍生的免疫原性组合物和方法

Country Status (8)

Country Link
US (3) US20130171185A1 (enExample)
EP (2) EP3153578A1 (enExample)
JP (3) JP2013533745A (enExample)
CN (1) CN103154242B (enExample)
AU (1) AU2011276328C1 (enExample)
CA (1) CA2804501C (enExample)
MX (1) MX2013000163A (enExample)
WO (1) WO2012006293A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
PT2590626E (pt) 2010-07-06 2016-01-26 Glaxosmithkline Biolog Sa Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
HUE058361T2 (hu) 2010-08-31 2022-07-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNA bejuttatására
ES2945135T3 (es) 2010-10-11 2023-06-28 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
RU2015132962A (ru) * 2013-01-10 2017-02-14 Новартис Аг Иммуногенные композиции на основе вируса гриппа и их применение
US9975923B2 (en) * 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP2970395A4 (en) * 2013-03-15 2017-03-29 The University of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
TW201629090A (zh) * 2014-08-07 2016-08-16 基亞生物科技股份有限公司 類病毒顆粒疫苗
KR102773575B1 (ko) * 2015-06-12 2025-02-27 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
KR101914779B1 (ko) 2016-03-18 2018-11-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
WO2017160124A2 (ko) * 2016-03-18 2017-09-21 연세대학교 산학협력단 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
EP3452493B1 (en) * 2016-05-04 2025-01-15 CureVac SE Nucleic acid molecules and uses thereof
WO2017214557A1 (en) 2016-06-10 2017-12-14 Counsyl, Inc. Nucleic acid sequencing adapters and uses thereof
EP3518974A4 (en) 2016-09-29 2020-05-27 Myriad Women's Health, Inc. NON-INVASIVE PRENATAL SCREENING USING DYNAMIC ITERATIVE DEEP OPTIMIZATION
WO2018144217A1 (en) 2017-01-31 2018-08-09 Counsyl, Inc. Methods and compositions for enrichment of target polynucleotides
US10968447B2 (en) 2017-01-31 2021-04-06 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
CA3056812C (en) * 2017-03-23 2022-11-29 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins
US11232850B2 (en) 2017-03-24 2022-01-25 Myriad Genetics, Inc. Copy number variant caller
WO2018182983A1 (en) * 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
PH12020550732A1 (en) 2017-11-30 2021-04-19 Medicago Inc Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
WO2020010428A1 (en) * 2018-07-13 2020-01-16 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
MX2021011059A (es) * 2019-03-12 2021-10-13 Icon Genetics Gmbh Particulas tipo norovirus con estabilidad mejorada.
BR112022013537A2 (pt) * 2020-01-08 2022-11-22 Bharat Biotech Int Ltd Composições de vacina viral e métodos de preparações das mesmas
CN114316033A (zh) * 2020-09-29 2022-04-12 香港理工大学深圳研究院 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用
CN115161343B (zh) * 2021-04-01 2024-06-04 苏州相奕生物技术有限公司 一种重组腺病毒表达载体及以其制备的多价诺如病毒疫苗
MX2024005194A (es) * 2021-10-27 2024-07-22 Univ Pennsylvania Vacuna de norovirus y métodos de su uso.
CN118871591A (zh) 2022-03-18 2024-10-29 电化株式会社 包含通过接头连接的衣壳蛋白的病毒样颗粒
WO2024144272A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gii mrna를 포함하는 백신 조성물
WO2024144262A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gi mrna를 포함하는 백신 조성물
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101153341A (zh) * 2007-09-21 2008-04-02 珠海市疾病预防控制中心 诺如病毒gⅱ型检测用引物、检测方法、检测试剂盒
WO2009039229A2 (en) * 2007-09-18 2009-03-26 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
NZ263538A (en) 1993-03-23 1996-10-28 Smithkline Beecham Biolog Vaccine compositions of 3-o-deacylated monophosphoryl lipid a
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2283557A1 (en) 1997-03-10 1998-09-17 Heather L. Davis Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
NZ504894A (en) 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
FR2771751B1 (fr) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
EP1797896A1 (en) 1998-10-16 2007-06-20 GlaxoSmithKline Biologicals SA Adjuvant systems and vaccines
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
WO2000079280A1 (en) 1999-06-22 2000-12-28 Japan As Represented By Director-General National Institute Of Infectious Diseases Srsv detection kit
AR025749A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
SI1354204T2 (sl) 2000-06-15 2010-09-30 Novartis Vaccines & Diagnostic Hcv antigen antitelo kombinacijska analiza
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
KR100894767B1 (ko) 2000-09-26 2009-04-24 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
EP1372708B1 (en) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
GB0123756D0 (en) 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
AU2003215193A1 (en) 2002-02-11 2003-09-04 Joseph D. Mosca Production of a protein delivery system for in vivo therapeutic treatment
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
EP1500699A1 (en) 2003-07-22 2005-01-26 Vivalis Production of vaccinia virus with adherent or non adherent avian cell lines
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US20050152911A1 (en) 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
WO2007053188A2 (en) 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
WO2007081447A2 (en) * 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP1979485A2 (en) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
WO2008145400A2 (en) 2007-05-31 2008-12-04 Medigene Ag Mutated structural protein of a parvovirus
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
CA2730083C (en) 2008-07-11 2016-11-01 The Administrators Of The Tulane Educational Fund Stimulus-responsive apta-chelamers
EP2324113B8 (en) * 2008-08-08 2018-04-04 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PL2853545T3 (pl) 2008-09-17 2016-12-30 Przeciwciało swoiste wobec IgE
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
MY159483A (en) 2008-11-26 2017-01-13 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039229A2 (en) * 2007-09-18 2009-03-26 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN101153341A (zh) * 2007-09-21 2008-04-02 珠海市疾病预防控制中心 诺如病毒gⅱ型检测用引物、检测方法、检测试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Multivalent norovirus vaccines induce strong mucosal and systemicblocking antibodies against multiple strains;Anna D. LoBue, ET AL;《Vaccine》;20060418;第24卷;5220-5234 *

Also Published As

Publication number Publication date
CA2804501C (en) 2021-01-26
US20160222066A1 (en) 2016-08-04
US10065994B2 (en) 2018-09-04
JP6351641B2 (ja) 2018-07-04
US20130171185A1 (en) 2013-07-04
AU2011276328A1 (en) 2013-02-28
JP2016053087A (ja) 2016-04-14
US20190023746A1 (en) 2019-01-24
CN103154242A (zh) 2013-06-12
MX2013000163A (es) 2013-03-05
AU2011276328C1 (en) 2016-01-21
CA2804501A1 (en) 2012-01-12
JP2013533745A (ja) 2013-08-29
JP2018086020A (ja) 2018-06-07
EP3153578A1 (en) 2017-04-12
EP2591097A1 (en) 2013-05-15
AU2011276328B2 (en) 2015-07-09
US10287324B2 (en) 2019-05-14
WO2012006293A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CN103154242B (zh) 诺如病毒衍生的免疫原性组合物和方法
US9744228B2 (en) Method for generating a parvovirus B19 virus-like particle
JP5215865B2 (ja) ノロウイルス抗原およびサポウイルス抗原
AU2012211278B2 (en) RSV immunization regimen
RS56157B1 (sr) Glikoproteinske čestice nalik virusu (vlp) besnila
EP4225776A1 (en) Fusion protein useful for vaccination against rotavirus
KR20190125470A (ko) 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물
EP4196160A2 (en) [sars-cov-2]-virus-like particle [vlp] vaccine: compositions, delivery strategies, methods and uses
TW202404629A (zh) 用於針對輪狀病毒疫苗接種之免疫原性組合物
AU2021333572A9 (en) Vaccines against sars-cov-2 infections
EP4225361A1 (en) Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
McCulloch Recombinant virus-like particles presenting epitopes for antibody generation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis Vaccines & Diagnostic

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant